(Ebook) Colon Cancer Diagnosis and Therapy: Volume 2 by Ganji Purnachandra Nagaraju; Dhananjay Shukla; Naveen Kumar Vishvakarma ISBN 9783030646677, 303064667X

(Ebook) Colon Cancer Diagnosis and Therapy: Volume 2 by Ganji Purnachandra Nagaraju; Dhananjay Shukla; Naveen Kumar Vishvakarma ISBN 9783030646677, 303064667X

Colorectal cancer (CRC) is a major global health challenge as the third leading cause for cancer related mortalities worldwide. Despite advances in therapeutic strategies, the five-year survival rate for CRC patients has remained the same over time due to the fact that patients are often diagnosed in advanced metastatic stages. Drug resistance is another common reason for poor prognosis. Researchers are now developing advanced therapeutic strategies such as immunotherapy, targeted therapy, and combination nanotechnology for drug delivery. In addition, the identification of new biomarkers will potentiate early stage diagnosis. This book is the second of three volumes on recent developments in colorectal diagnosis and therapy. Each volume can be read on its own, or together. Each volume focuses on different novel therapeutic advances, biomarkers, and identifies therapeutic targets for treatment. Written by leading international experts in the field, coverage addresses the role of diet habits and lifestyle in reducing gastrointestinal disorders and incidence of CRC. Chapters discuss current and future diagnostic and therapeutic options for colorectal cancer patients, focusing on immunotherapeutics, nanomedicine, biomarkers, and dietary factors for the effective management of colon cancer.
结直肠癌（CRC）是全球癌症相关死亡的第三大原因，是一项重大的全球健康挑战。尽管治疗策略取得了进展，但由于患者通常被诊断为晚期转移期，CRC患者的五年生存率随着时间的推移保持不变。耐药性是预后不良的另一个常见原因。研究人员现在正在开发先进的治疗策略，例如免疫疗法、靶向疗法和用于药物递送的联合纳米技术。此外，新生物标志物的鉴定将加强早期诊断。本书是关于结直肠诊断和治疗最新发展的三卷中的第二卷。每卷可以单独阅读，也可以一起阅读。每一卷都侧重于不同的新治疗进展、生物标志物，并确定治疗靶点。由该领域的国际领先专家撰写，报道涉及饮食习惯和生活方式在减少胃肠道疾病和结直肠癌发病率方面的作用。各章讨论了结直肠癌患者当前和未来的诊断和治疗选择，重点关注免疫疗法、纳米医学、生物标志物和有效管理结肠癌的饮食因素。